PA
QTWO icon

PharVision Advisers’s Q2 Holdings QTWO Stock Holding History

PharVision Advisers’s Portfolio QTWO Stock Details QTWO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,007
Closed -$290K – 947
2025
Q3 		$290K Buy
+4,007
New +$329K 0.16% 243

Other funds holding QTWO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.48B AUM 29.32% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's QTWO Position: Q4 2025 in Review

PharVision Advisers sold out of Q2 Holdings (QTWO) in Q4 2025, closing a stake of 4,007 shares — an estimated $290K sold.

PharVision Advisers first reported a position in QTWO in Q3 2025 and held it in 1 quarter. The position peaked at $290K in Q3 2025. 349 funds tracked by Wall St. Rank hold QTWO as of Q4 2025.

  • PharVision Advisers reported no remaining Q2 Holdings position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 4,007 Q2 Holdings shares in Q4 2025, an estimated $290K.
  • PharVision Advisers first reported a position in Q2 Holdings in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Q2 Holdings position peaked at $290K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Q2 Holdings as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.